Summit Therapeutics (NASDAQ: SMMT) - RICH TV LIVE PODCAST
Summit Therapeutics (NASDAQ: SMMT) - RICH TV LIVE PODCAST - December 8, 2022 - #summittherapeutics #pennystocks #richtvlive #business #news #finance #education
Summit Therapeutics, Inc. is honored to announce a definitive agreement of its partnership with Akeso Inc. (HKEX Code: 9926.HK, “Akeso”), to in-license its breakthrough bispecific antibody, ivonescimab. Akeso is a pioneer and source originator in developing innovative antibodies. The agreement supports Summit’s mission of developing and commercializing groundbreaking oncology pipeline products aimed at improving the quality of life of patients with serious unmet medical needs. For Akeso, the deal represents an opportunity to introduce its highly innovative antibodies to markets, including the United States, Canada, Europe, and Japan – an important step towards Akeso’s strategic intention of becoming a global biopharma organization.
Subscribe - https://www.youtube.com/c/RICHTVLIVE
Social Media Links - https://linktr.ee/richtvlive
Visit - http://richtv.io/ a community for stocks, cryptocurrency, nfts, metaverse, news, and trending topics. #richtvlive #richtv #richpicksdaily #stocks #business #news #finance #education #entertainment #money #defi #nft #metaverse #trading #stockmarket #podcast
Ledger - Home of the first and only certified Hardware wallets
https://bit.ly/richtv-Ledger
Popular Uploads - https://goo.gl/tbvXGg
Most Recent Upload - https://goo.gl/unKXBy
YouTube Channel Page - https://goo.gl/yUdG7w
Subscribe - http://www.youtube.com/c/RICHTVLIVE
Rich TV Live Playlist - https://goo.gl/e116JF
RICH TV LIVE TOP 10 STOCKS Playlist - https://www.youtube.com/playlist?list...
Disclaimer
RICH TV LIVE INC. company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RICH TV LIVE reports company profiles or other investor relations materials and presentations are subject to change. RICH TV LIVE and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.
Investing is inherently risky. RICH TV LIVE is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles or in other investor relations materials or presentations that it publishes electronically or in print.
We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov/Canadian CSA https://www.securities-administrators....
Ivonescimab, known as AK112 in China and Australia, and also as SMT112 in the United States, Canada, Europe, and Japan, is a novel, potential first-in-class bispecific antibody combining the power of immunotherapy via a blockade of PD-1 with the anti-angiogenesis benefits of an anti-VEGF into a single molecule. Ivonescimab is believed to be the PD-1 / VEGF bispecific antibody that is most advanced in the clinic: there are no known PD-1-based bispecific antibodies approved by the US Food and Drug Administration (“FDA”) or the European Medicines Agency (“EMA”).
Akeso has already demonstrated success by commercializing the only PD-1 bispecific. It’s product 开坦尼 (pronounced “Kaitanni”) (cadonilimab), a PD-1 / CTLA-4 bispecific, was approved by the Chinese National Medical Products Administration (“NMPA”) earlier this year for the treatment of relapsed or metastatic cervical cancer patients who progressed on or after platinum-based chemotherapy.
-
1:25:03
Fresh and Fit
6 hours agoWhy Millennials Are Wealthier Now Than Their Parents Were
68.1K23 -
1:20:38
Kim Iversen
8 hours agoPLANdemic 2.0: “MPox" Now Spreading To Europe and Asia, WHO Declares It An Emergency, What You Need To Know
69.3K108 -
1:38:24
Glenn Greenwald
8 hours agoMedia Coverage Restricted as DNC Kicks-Off in Chicago; Michael Tracey joins from the DNC; PLUS: Censorship Regime Keeps Escalating in the West | System Update #317
101K112 -
1:40:48
Donald Trump Jr.
10 hours agoDNC off to Dismal Start, What’s Next? Plus, Taking Your Questions Live! | TRIGGERED Ep.166
174K537 -
59:14
The StoneZONE with Roger Stone
6 hours agoCan Kamala Really Win? Top Dem Strategist Hank Sheinkopf Enters The StoneZONE to Discuss
69.4K11 -
4:09:01
Total Horse Channel
21 hours agoRegion 14 Arabian & Half-Arabian Championship Show | Monday Night Stream
57.1K2 -
57:40
Patriots With Grit
1 day agoAmerica's Broken Elections: Descending Us Into Chaos | Catherine Engelbrecht
43.1K3 -
8:28:06
FusedAegisTV
9 hours agoWFH InfoWARZ #46 | DNC Day 1, Protests Getting Spicy in Chicago, Bidens and Hillary Speak Tonight
68.9K19 -
1:40:57
2 MIKES LIVE
7 hours ago2 MIKES LIVE #105 Deep Dive Monday with Author Leo Lyon Zagami!
41.8K1 -
2:24:32
WeAreChange
8 hours agoMonkeypox Patients vs Palestine Supporters — Dems’ Implosion Coming?!
72.6K34